Moderna Underweight with $40 December 2026 Price Target
MRNA•JPMorgan resumed coverage on 14 large-cap biotech firms and assigned Moderna an Underweight rating with a $40 price target for December 2026, citing financial risks despite oncology progress. The bank highlighted sector-wide pipeline successes, margin expansion potential, and imminent clinical trial catalysts that could reshape growth trajectories.
1. JPMorgan Assigns Underweight Rating
JPMorgan’s analysts rated Moderna Underweight and set a $40 price target for December 2026, reflecting concerns over financial risks despite the company’s progress in applying its mRNA platform to oncology.
2. Sector Inflection Point Context
The firm described the biotech sector as entering a critical inflection point, with pipeline successes translating into profitable franchises and setting the stage for margin expansion across leading companies.
3. Clinical and Commercial Catalysts
Strategic diversification and upcoming clinical updates, including cardiovascular and renal outcomes trials in partnered drugs, were highlighted as potential catalysts that could influence the broader sector and Moderna’s future growth.
